Innova Captab Ltd

Innova Captab, a midcap pharmaceutical company, has faced significant stock declines, losing 5.74% on February 6, 2025, and 7.03% over two days. The stock has underperformed its sector and experienced a 20.51% drop in the past month, contrasting with the Sensex's slight gain.

Innova Captab has reported its financial results for the quarter ending December 2024, showcasing a significant year-on-year increase in Profit After Tax (PAT) to Rs 69.20 crore, reflecting strong operational performance. However, the company's stock evaluation has seen a notable adjustment in recent months.

Innova Captab, a midcap pharmaceutical company, experienced a notable rebound on January 29, 2025, reversing a three-day decline. The stock outperformed its sector and the Sensex, despite a monthly decline. Its moving averages indicate a mixed performance, with some averages positioned above and others below current levels.

Innova Captab, a midcap pharmaceutical company, faced a significant decline of 6.07% on January 28, 2025, amid broader sector challenges. The stock has seen consecutive losses over three days, totaling 14.86%, while remaining above longer-term moving averages despite recent underperformance compared to the Sensex.

Innova Captab, a midcap pharmaceutical company, faced a significant decline of 6.07% on January 28, 2025, amid broader sector challenges. The stock has seen consecutive losses over three days, totaling 14.86%, while remaining above longer-term moving averages despite recent underperformance compared to the Sensex.

Innova Captab, a midcap pharmaceutical company, faced a significant decline of 6.07% on January 28, 2025, amid broader sector challenges. The stock has seen consecutive losses over three days, totaling 14.86%, while remaining above longer-term moving averages despite recent underperformance compared to the Sensex.

Innova Captab, a midcap pharmaceutical company, has faced significant stock volatility, experiencing a decline over two consecutive days. Despite remaining above longer-term moving averages, the stock's recent performance contrasts with broader market trends, indicating challenges in its market position amid fluctuating conditions.

Innova Captab, a midcap pharmaceuticals company, saw a decline on January 24, 2025, underperforming its sector. Despite this drop, the stock has gained 3.30% over the past month, contrasting with the broader market's decline. Its moving averages indicate mixed performance, highlighting the stock's volatility.

Innova Captab, a midcap pharmaceutical company, experienced significant trading activity on January 23, 2025, achieving an intraday high and outperforming its sector. Over the past month, the stock has shown strong performance, maintaining a positive trend above several moving averages, while being recognized as a MOJO Stock since November 2024.

Innova Captab, a midcap pharmaceutical company, experienced a decline of 5.68% on January 22, 2025, with intraday lows reaching Rs 971.05. While the stock shows long-term stability above its 100-day and 200-day moving averages, it faces short-term challenges below its 5-day, 20-day, and 50-day averages.

Innova Captab, a midcap pharmaceutical company, experienced significant volatility on January 15, 2025, with intraday fluctuations between Rs 1,061 and Rs 986.9. The stock's moving averages indicate mixed performance, and it has seen a decline of 5.67% over the past month, outperforming the Sensex.

Innova Captab, a midcap pharmaceutical company, has faced a decline over four consecutive days, totaling 17.31%. Despite this downturn, the stock remains above key moving averages and has outperformed the broader sector and the Sensex over the past month, indicating a relatively stable position.

Innova Captab has recently undergone a revision in its score, reflecting the stock's recent performance challenges. Despite a notable decline in the short term, the company has shown resilience over the past month, outperforming the broader market. Additionally, Innova Captab has been added to MarketsMOJO's list, highlighting its potential in the pharmaceuticals sector.

Innova Captab has recently been added to MarketsMOJO's list following a revision in its score, reflecting its strong performance metrics. The stock reached a new 52-week high, showcasing impressive growth and resilience, significantly outperforming its sector and demonstrating a robust bullish trend over various moving averages.

Innova Captab has recently experienced a revision in its score, reflecting its strong market performance. The stock reached a new all-time high, outperforming its sector significantly. With consistent gains over the past eight days and robust trading above key moving averages, Innova Captab has been added to MarketsMOJO's list, underscoring its positive momentum.

Innova Captab has recently seen a revision in its score, reflecting its strong market performance and momentum. The stock reached a new 52-week high, showcasing significant growth over the past eight days and outperforming its sector. It has been added to MarketsMOJO's list, highlighting its competitive position in the pharmaceuticals industry.

Innova Captab has recently been added to MarketsMOJO's list following a revision in its score, reflecting its strong market performance. The stock reached a new 52-week high, outperforming its sector and demonstrating impressive momentum with significant gains over the past week, underscoring its robust position in the Pharmaceuticals & Drugs industry.

Innova Captab has experienced a significant adjustment in its evaluation, reflecting its strong performance in the pharmaceuticals sector. The stock has been added to MarketsMOJO's list, following a remarkable upward trend and consistent gains over the past week, showcasing its robust market position and resilience against broader market declines.